131 related articles for article (PubMed ID: 1739418)
1. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor.
Mikashima H; Ochi H; Muramoto Y; Hirotsu K; Arima N
Biochem Pharmacol; 1992 Jan; 43(2):295-9. PubMed ID: 1739418
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.
Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C
J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
4. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
[TBL] [Abstract][Full Text] [Related]
5. Correlation between pharmacokinetics and pharmacologic effects of a new imidazole thromboxane synthetase inhibitor.
Iwata T; Mikashima H; Takamatsu R
J Pharm Sci; 1990 Apr; 79(4):295-300. PubMed ID: 2352139
[TBL] [Abstract][Full Text] [Related]
6. Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase.
Takami M; Tsukada W
Pharmacol Res; 1998 Aug; 38(2):133-9. PubMed ID: 9721601
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
9. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
[TBL] [Abstract][Full Text] [Related]
10. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
12. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
[TBL] [Abstract][Full Text] [Related]
14. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.
Reilly IA; FitzGerald GA
Blood; 1987 Jan; 69(1):180-6. PubMed ID: 3790723
[TBL] [Abstract][Full Text] [Related]
16. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action.
Ushiyama S; Ito T; Asai F; Oshima T; Terada A; Matsuda K; Yamazaki M
Thromb Res; 1988 Sep; 51(5):507-20. PubMed ID: 3175990
[TBL] [Abstract][Full Text] [Related]
17. Production of thromboxane A2 and prostaglandin i2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis.
Kaneko N; Masuyama J; Nara H; Hirata D; Iwamoto M; Okazaki H; Minota S; Yoshio T
J Rheumatol; 2002 Oct; 29(10):2106-13. PubMed ID: 12375319
[TBL] [Abstract][Full Text] [Related]
18. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
